Patient equity and respiratory syncytial virus Immunoprophylaxis
Abstract An analysis of benefit and cost is critical for independent advisory groups that provide evidence-based recommendations. In many countries, the role of RSV immunoprophylaxis for infants at increased risk of hospitalization is controversial because of limited benefit and high cost. The repor...
Main Author: | H. Cody Meissner |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-01-01
|
Series: | Israel Journal of Health Policy Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13584-019-0288-6 |
Similar Items
-
Passive Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now?
by: Alessandro Rocca, et al.
Published: (2021-04-01) -
Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil
by: Roseane Porfírio de Souza, et al.
Published: (2019-08-01) -
Temporal-spatial analysis of hospitalizations for bronchiolitis in Brazil: prediction of epidemic regions and periods for immunization against the Respiratory Syncytial Virus
by: Edilenia Queiroz Pereira, et al.
Published: (2023-03-01) -
Prevention and treatment of respiratory syncytial virus bronchiolitis and postbronchiolitic wheezing
by: Kimpen Jan LL
Published: (2002-06-01) -
Respiratory-syncytial virus immunoprophylaxis on asthma symptoms development in prematurity with bronchopulmonary dysplasia
by: Li-Ching Fang, MD, et al.
Published: (2023-11-01)